Short report of a phase II trial of nintedanib in recurrent malignant pleural mesothelioma (MPM)
Bryan Schneider,Bobby Daly,Wei Chen,Jaclyn Ventimiglia,Misako Nagasaka,Antoinette J. Wozniak,Gregory P. Kalemkerian,Marjorie G. Zauderer
DOI: https://doi.org/10.1016/j.cllc.2023.04.004
IF: 4.84
2023-04-09
Clinical Lung Cancer
Abstract:Background Malignant pleural mesothelioma (MPM) is a disease for which there remains an unmet need for better therapeutic options. Nintedanib is an oral multikinase inhibitor impacting VEGF, FGF, PDGFR, and other kinase activity such as TGFß signaling pathways. We conducted a phase II trial of nintedanib in patients with recurrent MPM. Methods Patients with MPM previously treated with platinum-based chemotherapy, performance status (PS) 0-1, adequate organ function, and no contraindications to anti-angiogenic therapy were eligible and were treated with nintedanib 200 mg twice per day until disease progression or unacceptable toxicity. The primary endpoint was 4-month progression-free survival (PFS). Results Twenty patients were enrolled. The median age was 70 years (range 32-81), 90% were male, and 80% were PS 1. The histology was 70% epithelioid, 5% sarcomatoid, 10% biphasic, and 15% unknown. 15% had prior bevacizumab. The median follow-up was 4.1 mo. There were no responses but 40% had stable disease at 8 weeks. The median PFS was 1.8 mo. (95% CI: 1.68, 3.55) and the 4-month PFS rate was 13%. The median OS was 4.2 mo. (95% CI: 2.53, 8.74) and the 4-month OS rate was 55%. Toxicities were primarily grade 1-2 and included diarrhea, fatigue, edema, transaminase elevation, anorexia, nausea, vomiting and dyspnea. Conclusions The activity of nintedanib in previously treated MPM patients was. modest. The trial did not meet its primary PFS endpoint. Even though 2 patients had prolonged stable disease for >4 months, the efficacy of nintedanib remains unproven. Micro This is a Phase II trial assessing the efficacy of nintedanib, an oral multi-targeted kinase inhibitor, in patients with recurrent malignant pleural mesothelioma. The drug was well tolerated but the activity was modest with no responses and 40% stable disease at 8 weeks. The trial did not meet its endpoint but there was a subset of patients who had prolonged stable disease. Clinical Practice Points 1) Novel therapies are needed for the treatment of malignant pleural mesothelioma (MPM). 2) Agents targeting angiogenesis such as bevacizumab have a role in the treatment of MPM. 3) Nintedanib had modest activity involving prolonged stable disease in a small group of patients. 4) Immunotherapy is now important in the treatment of MPM but angiogenesis inhibitors in combination with immunotherapy and/or chemotherapy may still have a role. 5) It is very important to discover biomarkers that can help with patient selection to individualize treatment. 6) Participation in clinical trials evaluating novel agents remains very important in advancing treatment strategies.
oncology